Citadel Advisors
CANF

Citadel Advisors’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Citadel Advisors’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7
Closed -$25K – 9225
2018
Q2 		$25K Buy
+7
New +$27.9K ﹤0.01% 8595

Other funds holding CANF

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's CANF Position: Q2 2026 in Review

Citadel Advisors reduced its Can-Fite BioPharma American Depositary Shares (CANF) stake by 4.7% in Q2 2026, selling an estimated $5.05K and leaving 32,533 shares worth $96.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12725.

Citadel Advisors first reported a position in CANF in Q1 2015 and has held it in 13 quarters since. The position peaked at $148K in Q1 2021. 8 funds tracked by Wall St. Rank hold CANF as of Q2 2026.

  • Citadel Advisors held 32,533 shares of Can-Fite BioPharma American Depositary Shares worth $96.6K as of Q2 2026.
  • Citadel Advisors sold 1,617 Can-Fite BioPharma American Depositary Shares shares in Q2 2026, an estimated $5.05K.
  • Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12725 holding.
  • Citadel Advisors first reported a position in Can-Fite BioPharma American Depositary Shares in Q1 2015 and has held it in 13 quarters since.
  • Citadel Advisors's Can-Fite BioPharma American Depositary Shares position peaked at $148K in Q1 2021.
  • 8 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.